GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TherapeuticsMD Inc (STU:29TA) » Definitions » Cyclically Adjusted PS Ratio

TherapeuticsMD (STU:29TA) Cyclically Adjusted PS Ratio : 0.33 (As of May. 17, 2024)


View and export this data going back to 2014. Start your Free Trial

What is TherapeuticsMD Cyclically Adjusted PS Ratio?

As of today (2024-05-17), TherapeuticsMD's current share price is €1.90. TherapeuticsMD's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €5.75. TherapeuticsMD's Cyclically Adjusted PS Ratio for today is 0.33.

The historical rank and industry rank for TherapeuticsMD's Cyclically Adjusted PS Ratio or its related term are showing as below:

STU:29TA' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.06   Med: 1.02   Max: 5.85
Current: 0.33

During the past years, TherapeuticsMD's highest Cyclically Adjusted PS Ratio was 5.85. The lowest was 0.06. And the median was 1.02.

STU:29TA's Cyclically Adjusted PS Ratio is ranked better than
90.63% of 747 companies
in the Drug Manufacturers industry
Industry Median: 2.17 vs STU:29TA: 0.33

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

TherapeuticsMD's adjusted revenue per share data for the three months ended in Mar. 2024 was €0.025. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €5.75 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


TherapeuticsMD Cyclically Adjusted PS Ratio Historical Data

The historical data trend for TherapeuticsMD's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TherapeuticsMD Cyclically Adjusted PS Ratio Chart

TherapeuticsMD Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.64 2.88 3.04 0.85 0.35

TherapeuticsMD Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 0.62 0.46 0.35 0.36

Competitive Comparison of TherapeuticsMD's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, TherapeuticsMD's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TherapeuticsMD's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TherapeuticsMD's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where TherapeuticsMD's Cyclically Adjusted PS Ratio falls into.



TherapeuticsMD Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

TherapeuticsMD's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1.90/5.75
=0.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TherapeuticsMD's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, TherapeuticsMD's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.025/131.7762*131.7762
=0.025

Current CPI (Mar. 2024) = 131.7762.

TherapeuticsMD Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.949 100.560 1.244
201409 1.067 100.428 1.400
201412 1.106 99.070 1.471
201503 1.265 99.621 1.673
201506 1.250 100.684 1.636
201509 1.305 100.392 1.713
201512 1.452 99.792 1.917
201603 1.136 100.470 1.490
201606 0.998 101.688 1.293
201609 1.255 101.861 1.624
201612 1.082 101.863 1.400
201703 0.942 102.862 1.207
201706 0.930 103.349 1.186
201709 0.891 104.136 1.127
201712 0.821 104.011 1.040
201803 0.707 105.290 0.885
201806 0.743 106.317 0.921
201809 0.653 106.507 0.808
201812 0.937 105.998 1.165
201903 0.725 107.251 0.891
201906 1.115 108.070 1.360
201909 4.464 108.329 5.430
201912 2.732 108.420 3.321
202003 2.042 108.902 2.471
202006 1.747 108.767 2.117
202009 3.012 109.815 3.614
202012 3.237 109.897 3.881
202103 2.403 111.754 2.834
202106 2.422 114.631 2.784
202109 2.557 115.734 2.911
202112 -6.797 117.630 -7.614
202203 0.073 121.301 0.079
202206 0.038 125.017 0.040
202209 0.039 125.227 0.041
202212 5.975 125.222 6.288
202303 0.040 127.348 0.041
202306 0.039 128.729 0.040
202309 -0.005 129.860 -0.005
202312 0.042 129.419 0.043
202403 0.025 131.776 0.025

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


TherapeuticsMD  (STU:29TA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


TherapeuticsMD Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of TherapeuticsMD's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


TherapeuticsMD (STU:29TA) Business Description

Traded in Other Exchanges
Address
951 Yamato Road, Suite 220, Boca Raton, FL, USA, 33431
TherapeuticsMD Inc is a major drug manufacturing with a focus on creating and commercializing products targeted exclusively for women. The company intends to commercialize advanced hormone therapy pharmaceutical products. TherapeuticsMD's drug candidates that have completed clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and discomfort. The company relies on third parties for the production of clinical and commercial quantities of its drug candidates.

TherapeuticsMD (STU:29TA) Headlines

No Headlines